Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.

Chae YK, Wang S, Nimeiri H, Kalyan A, Giles FJ.

Oncotarget. 2017 Jun 3;8(34):57889-57897. doi: 10.18632/oncotarget.18361. eCollection 2017 Aug 22.

2.

Pseudoprogression and hyperprogression after checkpoint blockade.

Wang Q, Gao J, Wu X.

Int Immunopharmacol. 2018 May;58:125-135. doi: 10.1016/j.intimp.2018.03.018. Epub 2018 Mar 23. Review.

PMID:
29579717
3.

Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.

Michalarea V, Fontana E, Garces AI, Williams A, Smyth EC, Picchia S, Rao S, Chau I, Cunningham D, Bali MA.

Curr Probl Cancer. 2019 Feb 21. pii: S0147-0272(18)30318-0. doi: 10.1016/j.currproblcancer.2019.01.008. [Epub ahead of print]

PMID:
30827742
4.

[A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].

Wang X, Zhao Y, Chen Z.

Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):389-394. doi: 10.3779/j.issn.1009-3419.2019.06.10. Chinese.

5.

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.

Zhao P, Li L, Jiang X, Li Q.

J Hematol Oncol. 2019 May 31;12(1):54. doi: 10.1186/s13045-019-0738-1. Review.

6.

Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001974. doi: 10.1101/mcs.a001974. Print 2017 Sep.

7.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

8.

Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer.

Miyauchi T, Yaguchi T, Kawakami Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):54-59. doi: 10.2177/jsci.40.54. Review.

9.

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S.

Cancer Treat Rev. 2016 Jul;48:61-8. doi: 10.1016/j.ctrv.2016.06.008. Epub 2016 Jun 18. Review.

PMID:
27362548
10.
11.

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.

Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM, Kang WK, Kim S, Kim KM.

Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519.

12.

Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.

Llosa NJ, Luber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, Durham JN, Sears CL, Le DT, Diaz LA Jr, Pardoll DM, Wang H, Housseau F, Anders RA.

Cancer Immunol Res. 2019 Oct;7(10):1574-1579. doi: 10.1158/2326-6066.CIR-18-0927. Epub 2019 Aug 22.

PMID:
31439614
13.

[Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression].

Foller S, Oppel-Heuchel H, Grimm MO.

Urologe A. 2018 Nov;57(11):1316-1325. doi: 10.1007/s00120-018-0788-y. Review. German.

PMID:
30334063
14.
15.

Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma.

Kubecek O, Trojanova P, Molnarova V, Kopecky J.

Med Hypotheses. 2016 Aug;93:74-6. doi: 10.1016/j.mehy.2016.05.023. Epub 2016 May 21.

PMID:
27372860
16.

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy.

Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC, Lu B.

J Hematol Oncol. 2016 Sep 23;9(1):96.

17.

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.

Kim EY, Park I, Kim YS, Ahn HK, Lee HY, Kim JH.

Thorac Cancer. 2019 Apr;10(4):1016-1018. doi: 10.1111/1759-7714.12994. Epub 2019 Feb 7.

18.

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment.

Vander Jagt TA, Davis LE, Thakur MD, Franz C, Pollock JM.

Radiol Case Rep. 2018 Jul 3;13(4):882-885. doi: 10.1016/j.radcr.2018.05.013. eCollection 2018 Aug.

19.

Tumor pseudoprogression of spinal metastasis after radiosurgery: a novel concept and case reports.

Taylor DR, Weaver JA.

J Neurosurg Spine. 2015 May;22(5):534-9. doi: 10.3171/2014.10.SPINE14444. Epub 2015 Feb 6.

PMID:
25658469
20.

Supplemental Content

Support Center